PepGen Inc.

NASDAQ:PEPG

Biotechnology

Healthcare
$3.83 +5.29%

+$0.09 today

Market cap
$265.27M
Beta
1.93
P/E (TTM)
-1.6
EPS (TTM)
-$1.12
52W Low $1.01High $7.80

Volume 3.39M

Average 1.37M

PEPG Free Cash Flow

Operating cash flow minus capital expenditures: cash available for debt repayment, dividends, and buybacks.

PepGen Inc.NASDAQ: PEPG

Free Cash Flow · Q1 FY2026 · quarter ended Mar 2026

Free cash flow declines year over year

Q1 FY2026 free cash flow of $18.43M (cash outflow) fell 20.1% year over year, behind the -7.3% change in trailing-twelve-month free cash flow. Sequentially, it rose 16.3% from the prior quarter. Over 3 fiscal years it compounded at +9.1% a year.

Context

  • Free cash flow grew in size in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -20.1% toward the trailing-twelve-month pace of -7.3%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$18.43M+16.3% QoQ
Last fiscal yearDec 2025
-$81.9M-1.2% YoY
LTMMar 2026
-$77.27M-7.3% YoY
Free Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-20.1%——
1 year-1.2%——
3-year CAGR+9.1%——
5-year CAGR——
10-year CAGR——

Free Cash Flow history

USD · from the cash flow

Latest · FY2025
(81.9M) USD
Year-over-year change
+1.2%

Free Cash Flow vs competitors

How PEPG compares with its peers on the latest reported figures

  • Peers report in different currencies, so free cash flow is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -7.3% is the 3rd highest of 8, against a peer median of -12.4%.
  • Over three fiscal years its annual growth of +9.1% compares with a peer median of +10.2%.
PEPG Competitors
Free Cash Flow for PEPG and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ALECAlector, Inc.LTM Mar 2026$173.2M USD-24.7%+96.0%940.4%
FATEFate Therapeutics, Inc.LTM Mar 2026$108.09M USD-13.6%-26.6%1711.4%
NKTXNkarta, Inc.LTM Mar 2026$88.39M USD-16.3%-4.8%—
PEPGPepGen Inc.LTM Mar 2026$77.27M USD-7.3%+9.1%—
CRBPCorbus Pharmaceuticals Holdings, Inc.LTM Mar 2026$73.65M USD+46.6%+19.8%—
MOLNMolecular Partners AGLTM Mar 2026CHF 54.13M CHF-8.4%——
ELTXElicio Therapeutics, Inc.LTM Mar 2026$38.49M USD+9.5%+17.4%—
CRDFCardiff Oncology, Inc.LTM Mar 2026$37.46M USD-12.4%+3.0%7135.4%
Peer median (excluding PEPG) —-12.4%+10.2%1711.4%

Competitors are the stored peer set for PEPG. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(27.28M)(69.1M)(78.63M)(89.98M)(89.66M)
Depreciation & Amortization178K493K850K5.25M5.15M
Deferred Income Tax00000
Stock-Based Compensation1.53M4.76M7.05M11.46M10.61M
Change in Working Capital2.77M4.51M1.95M(5.25M)(6.22M)
Accounts Receivables(4.34M)4.18M26K00
Inventory00000
Accounts Payables2.51M(1.41M)(369K)722K(935K)
Other Working Capital4.61M1.73M2.29M(5.97M)(5.29M)
Other Non-Cash Items196K76K(220K)(3.86M)(1.51M)
Operating Cash Flow(22.6M)(59.27M)(69M)(82.37M)(81.64M)
Capital Expenditures(500K)(3.76M)(2.6M)(497K)(264K)
Acquisitions (Net)00000
Purchases of Investments00(29.4M)(145.17M)(93.97M)
Sales of Investments000108M79M
Other Investing Activities00000
Investing Cash Flow(500K)(3.76M)(32M)(37.67M)(15.24M)
Debt Repayment00000
Common Stock Issued0114.27M086.78M108.1M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(1.39M)(2.07M)(189K)1.97M0
Financing Cash Flow147.66M112.19M(189K)88.75M107.98M
Effect of Forex Changes33K(316K)286K(62K)(16K)
Net Change in Cash124.59M48.86M(100.9M)(31.35M)11.09M
Free Cash Flow(23.1M)(63.02M)(71.6M)(82.87M)(81.9M)

PepGen Inc.

NASDAQ:PEPG

Intrinsic Alpha fair value

Locked

Current Price

$3.83

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.